Doxorubicin activity is enhanced by hyperthermia in a model of ex vivo vascular perfusion of human colon carcinoma
/in Colorectal Cancer, Hyperthermia, International Publications /von 2003-05-13 / World J Surg 2003 Jun;27(6):640-6Dendritic cell vaccination: new hope for the treatment of metastasized endocrine malignancies
/in Dendritic Cells, International Publications, Thyroid Cancer /von 2003-05-01 / Trends Endocrinol. Metab. 2003 May-Jun;14(4):156-62TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients
/in International Publications, Ovarian Cancer /von 2003-04-01 / Clin. Cancer Res. 2003 Apr;9(4):1517-27Dendritic cell-based immunotherapy for the treatment of hematological malignancies
/in Acute Leukemia, Dendritic Cells, International Publications, Multiple Myeloma /von 2003-04-01 / Hematology 2003 Apr;8(2):97-104[Clinical research on the treatment effect of autologous dendritic cell vaccine on the patients with chronic hepatitis B]
/in Chronic Virus Hepatitis, International Publications /von 2003-04-01 / Zhonghua Gan Zang Bing Za Zhi 2003 Apr;11(4):206-8[Immune response of dendritic cells acquiring antigens from apoptotic cholangiocarcinoma cells induced by mitomycin]
/in Gallbladder Cancer, International Publications /von 2003-03-01 / Zhonghua Gan Zang Bing Za Zhi 2003 Mar;11(3):149-52Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract
/in Colorectal Cancer, International Publications /von 2003-03-01 / World J. Gastroenterol. 2003 Mar;9(3):495-8In vivo induction of dendritic cell-mediated cytotoxicity against allogeneic pancreatic carcinoma cells
/in International Publications, Pancreatic Cancer /von 2003-03-01 / Int. J. Oncol. 2003 Mar;22(3):651-6Ifosfamide, carboplatin and etoposide combined with 41.8 degrees C whole body hyperthermia for malignant pleural mesothelioma
/in Hyperthermia, International Publications, Malignant Pleural Mesothelioma, NSCLC /von 2003-03-01 / Lung Cancer 2003 Mar;39(3):339-45
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de